Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/23/2008US20080262046 Amidopropoxyphenyl Orexin Receptor Antagonists
10/23/2008US20080262045 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12
10/23/2008US20080262043 free acid Form III; precipitating it from a mixture of ethyl acetate and water after the oxidation of 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole with peracetic acid; pantoprazole sodium and pantoprazole sodium sesquihydrate
10/23/2008US20080262042 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker
10/23/2008US20080262041 Beta-Lactams for Treatment of Cns Disorders
10/23/2008US20080262040 novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates
10/23/2008US20080262039 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions
10/23/2008US20080262038 4-[(4-aminophenyl)(1-benzylpiperidin-4-ylidene)methyl]-N,N-diethylbenzamide; management of pain, anxiety and functional gastrointestinal disorders; delta agonist
10/23/2008US20080262037 Piperidine Derivatives for the Treatment of Chemokine Mediated Disease
10/23/2008US20080262036 Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof
10/23/2008US20080262035 Amide Derivatives as Inhibitors of Histone Deacetylase
10/23/2008US20080262034 selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect;
10/23/2008US20080262033 hypogonadism and male infertility; ovulation induction
10/23/2008US20080262032 Isoxazoline Derivative and Novel Process for Its Preparation
10/23/2008US20080262031 4-Aminoquinoline Derivatives as Antimalarials
10/23/2008US20080262030 Drug for psychological and central nervous system disorders
10/23/2008US20080262029 Acid and Base Salt Forms of Gaboxadol
10/23/2008US20080262028 Imidazole derivatives as inhibitors of tafia
10/23/2008US20080262027 5Z)-2-[(2,6-Dichlorophenyl)amino]-5-{[3-(4-morpholinyl)-6-quinoxalinyl]methylidene}-1,3-thiazol-4(5H)-one; inhibiting hYAK3 proteins; autoimmunity, HIV, cancer, drug-induced anemias, myelodysplastic syndrome, aplastic anemia myelosuppression, cytopenia
10/23/2008US20080262026 1-(2,4-dichlorophenyl)-2-{4-[(3,3-difluoropyrrolidin-1-yl)methyl]phenyl}-3-methyl-5-piperidin-1-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one; obesity, psychiatric and neurological disorders
10/23/2008US20080262025 Processes for the Preparation of Zolpidem and its Hemitartrate
10/23/2008US20080262024 Rifaximin compositions and method of use
10/23/2008US20080262023 Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof
10/23/2008US20080262022 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine; applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks
10/23/2008US20080262021 [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia
10/23/2008US20080262020 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites
10/23/2008US20080262019 Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole
10/23/2008US20080262018 Treating allergic and inflammatory conditions
10/23/2008US20080262017 human ingestion, that are sugar free, clear in color; loratadine, desloratadine, or a pharmaceutically acceptable salt
10/23/2008US20080262016 Isoquinoline derivatives and methods of use thereof
10/23/2008US20080262015 therapeutically active 2,4,5-trisubstituted imidazole compounds; alone or in combination; high antineoplastic activity, low systemic toxicity and low mutagenicity on normal cells; inhibitors of p38 MAP kinase; modulators of multi-drug resistance in cancer cells
10/23/2008US20080262014 Use of Camptothecin Derivatives for the Treatment of Proliferative Diseases in a Fixed Dosing Regimen
10/23/2008US20080262013 Oxymorphone controlled release formulations
10/23/2008US20080262012 polymorphic forms alpha , beta and gamma; for the oral or topical route; In case of invasive bacteria, it may be useful to use the most bioavailable polymorphic form, whereas in case of non-invasive pathogens it may be more appropriate to use the less adsorbed forms, since they are safer
10/23/2008US20080262011 N-(2-hydroxy-1-methyl-ethyl)-3-iodobenzamide; for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors; modulates cannabinoid receptors
10/23/2008US20080262010 dissolving with D-glucoronic acid in one or more solvents; and precipitating one crystalline polymorph as the D-glucoronate salt; kinase-inhibiting
10/23/2008US20080262009 dissolving an amount of compound and acetic acid as a mixture, in one or more solvents; and precipitating one crystalline polymorph of the compound as the acetate salt from the mixture
10/23/2008US20080262008 useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph
10/23/2008US20080262007 replication inhibitors; improved ability to inhibit the replication of mutant strains, in particular strains which have become resistant to one or more known NNRTI drugs (Non Nucleoside Reverse Transcriptase Inhibitor drugs)
10/23/2008US20080262006 Selective endothelin type-a antagonists
10/23/2008US20080262005 Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto
10/23/2008US20080262004 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridine; to treat autoimmune disorders like rheumatoid arthritis, glomerulonephritis, neoplasms; antifibrotic agents
10/23/2008US20080262003 Methods for treating neoplasia with combination of chemotherapeutic agents and radiation
10/23/2008US20080262002 Use of S-Adenosylmethionine, Vitamin E, and Vitamin C for the Treatment of Oxidative Liver Injury or Insulin Resistance
10/23/2008US20080262001 Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
10/23/2008US20080261999 Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
10/23/2008US20080261998 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
10/23/2008US20080261997 Use of aminoindazole derivatives for the inhibition of tau phosphorylation
10/23/2008US20080261996 Substituted propiolic acid amides and their use for producing drugs
10/23/2008US20080261995 treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence; sildenafil and dutasteride
10/23/2008US20080261994 4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester; aggrecanase and matrix metalloproteinase (with zinc in the catalytic active center) inhibitor; antiarthritic agent: osteoarthritis, rheumatoid arthritis
10/23/2008US20080261992 Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor
10/23/2008US20080261991 Reducing Side Effects of Tramadol
10/23/2008US20080261990 2-({4-[((2-Furylmethyl) {[6(4-methylphenyl)pyrimidin-4-yl]methyl}amino)methyl]phenyl}thio)-2-methylpropanoic acid; dyslipidemias, arteriosclerosis, coronary heart disease, thrombosis and metabolic syndrome
10/23/2008US20080261989 Quinoxaline Inhibitors of the Hedgehog Signalling
10/23/2008US20080261988 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
10/23/2008US20080261987 Substituted piperazines
10/23/2008US20080261986 Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
10/23/2008US20080261985 treating a disorder characterized by the overexpression of iNOS or COX-2 genes; rheumatoid arthritis, inflammatory bowel disease, lupus, multiple sclerosis, or psoriasis; cancer
10/23/2008US20080261984 Use of S,S-Reboxetine in the Treatment of Pain
10/23/2008US20080261983 5HT4 serotonin receptor agonist; chronic gastritis; heartburn; nausea and vomiting; and gastroesophageal reflux disease; coadministration with proton pump inhibitor; an H2 antagonist; an anti-flatulent; and pancreatin; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl-d2)benzamide
10/23/2008US20080261982 autoimmune disease and liver cirrhosis; useful for killing hyperproliferating cells
10/23/2008US20080261981 3-{4-[4-(2-amino-3-morpholin-4-yl-3-oxo-propyl)-phenoxy]-phenyl}-N-hydroxypropionamide hydrochloride; for reducing blood glucose, free fatty acids, cholesterol, triglycerides levels
10/23/2008US20080261980 4-{5-[3-(3,4,5-trimethoxybenzyl)-4-oxo-2-thioxo-thiazolidine-5-ylidenemethyl]-furan-2-yl}benzoic acid; inhibition of the interaction between HIF-1 alpha and p300
10/23/2008US20080261979 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals
10/23/2008US20080261978 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea
10/23/2008US20080261977 Pyrimidine Derivatives as Cannabinoid Receptor Modulators
10/23/2008US20080261976 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
10/23/2008US20080261975 Including Itk kinase; 1-[2-[4-(3-Dimethylamino-propoxy)-phenyl]-4-methyl-5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-methyl-propan-2-ol; inflammation, immunological and allergic disorders
10/23/2008US20080261974 Novel Chemical Compounds
10/23/2008US20080261973 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors
10/23/2008US20080261972 Cgrp Receptor Antagonists
10/23/2008US20080261971 Novel Heterocyclic Nf-Kb Inhibitors
10/23/2008US20080261970 metabolic syndrome; diabetes; obesity; N-(2-(benzyloxy)-1-(6-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-1-methylpiperidine-4-sulfonamide
10/23/2008US20080261969 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
10/23/2008US20080261968 Heterobicyclic metalloprotease inhibitors
10/23/2008US20080261967 Modulators of Central Nervous System Neurotransmitters
10/23/2008US20080261966 Bis-aryl sulfonamides
10/23/2008US20080261965 Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
10/23/2008US20080261964 Substituted quinolones II
10/23/2008US20080261963 antibiotics, fungicides, viricides; treating microbial infections; fused rings based on 4-oxo-4H-pyrido[3,2,1-kl]benzo[g]-phenoxazine for example; Tumor suppression agents with reduced side effects; anticancer
10/23/2008US20080261962 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
10/23/2008US20080261961 Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
10/23/2008US20080261960 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
10/23/2008US20080261959 Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
10/23/2008US20080261958 Combination of Organic Compounds
10/23/2008US20080261957 3'-(8-Methyl-4-oxo-7-trifluoromethyl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-biphenyl-4-sulfonic acid amide; metabotropic glutamate receptor antagonist; prodrug; advantages in absorption, pharmacokinetics, in distribution and transport to brain; central nervous system disorder
10/23/2008US20080261956 Substituted Phenols as Active Agents Inhibiting Vegf Production
10/23/2008US20080261955 disorders associated with noradreanaline reuptake, such as attention deficit disorder, Chronic Fatigue Syndrome, fibromyalgia, and depression with pain
10/23/2008US20080261954 derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. Galanthamine, narwedine and lycoramine, or from metabolites of said compounds
10/23/2008US20080261953 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
10/23/2008US20080261952 treating a condition associated with the cannabinoid -1 receptor; 2-[3-(4-Fluorophenyl)ureido]-4-methylthiazole-5-carboxylic acid ethyl ester
10/23/2008US20080261951 Condensed azepines as vasopressin agonists
10/23/2008US20080261950 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory
10/23/2008US20080261949 ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether
10/23/2008US20080261948 Ligands for G-Protein Coupled Receptors
10/23/2008US20080261947 Poly(ADP-ribose)polymerase inhibitor; ischemic diseases, cerebral infarction, antiretroviral, sensitizer for anticancer therapy, immunosuppressant; 5,6,7,8-tetrahydrophthalazin-1(2H)-one compounds; 2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one compounds
10/23/2008US20080261946 Pyrimidine Compounds for the Treatment of Inflammatory Disorders
10/23/2008US20080261945 Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine
10/23/2008US20080261944 Indole Derivatives as Antiviral Agents
1 ... 3029 3030 3031 3032 3033 3034 3035 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 ... 7860